中华病理学杂志
中華病理學雜誌
중화병이학잡지
Chinese Journal of Pathology
2012年
3期
168-171
,共4页
冼丽芳%黄香婷%文剑明%叶玉清
冼麗芳%黃香婷%文劍明%葉玉清
승려방%황향정%문검명%협옥청
胃肿瘤%基因,erbB-2%原位杂交,荧光
胃腫瘤%基因,erbB-2%原位雜交,熒光
위종류%기인,erbB-2%원위잡교,형광
Stomach neoplasms%Genes,erbB-2%In situ hybridization,fluorescence
目的 探讨胃癌HER2基因扩增状态及其基因产物蛋白表达,以协助临床筛选抗HER2靶向治疗患者.方法 收集胃癌活检标本共85例,进行HER2基因扩增和蛋白表达检测.HER2基因扩增状态采用双重原位杂交检测(HER2 dual-ISH detection),而HER2基因蛋白采用免疫组织化学[全程在全自动染色机(Ventana)]进行检测.结果 85例胃癌病例中,有HER2基因扩增10例,扩增率为11.8％,无扩增75例,占88.2％.在有HER2基因扩增的10例病例中,7例HER2蛋白免疫组织化学为3+,2例为2+,1例为-/1+；75例无基因扩增的病例,HER2蛋白免疫组织化学3+为0例、2+为18例(24.0％),-/1+为57例(76.0％).HER2基因扩增与HER2蛋白表达的相符率为77.6％.组织学上,有HER2阳性扩增的胃癌绝大多数为中等分化管状腺癌.结论 双重原位杂交技术是检测胃癌活检组织HER2基因扩增的可靠和客观方法.临床上,仅少数有HER2基因扩增的胃癌适合抗HER2靶向治疗.
目的 探討胃癌HER2基因擴增狀態及其基因產物蛋白錶達,以協助臨床篩選抗HER2靶嚮治療患者.方法 收集胃癌活檢標本共85例,進行HER2基因擴增和蛋白錶達檢測.HER2基因擴增狀態採用雙重原位雜交檢測(HER2 dual-ISH detection),而HER2基因蛋白採用免疫組織化學[全程在全自動染色機(Ventana)]進行檢測.結果 85例胃癌病例中,有HER2基因擴增10例,擴增率為11.8％,無擴增75例,佔88.2％.在有HER2基因擴增的10例病例中,7例HER2蛋白免疫組織化學為3+,2例為2+,1例為-/1+；75例無基因擴增的病例,HER2蛋白免疫組織化學3+為0例、2+為18例(24.0％),-/1+為57例(76.0％).HER2基因擴增與HER2蛋白錶達的相符率為77.6％.組織學上,有HER2暘性擴增的胃癌絕大多數為中等分化管狀腺癌.結論 雙重原位雜交技術是檢測胃癌活檢組織HER2基因擴增的可靠和客觀方法.臨床上,僅少數有HER2基因擴增的胃癌適閤抗HER2靶嚮治療.
목적 탐토위암HER2기인확증상태급기기인산물단백표체,이협조림상사선항HER2파향치료환자.방법 수집위암활검표본공85례,진행HER2기인확증화단백표체검측.HER2기인확증상태채용쌍중원위잡교검측(HER2 dual-ISH detection),이HER2기인단백채용면역조직화학[전정재전자동염색궤(Ventana)]진행검측.결과 85례위암병례중,유HER2기인확증10례,확증솔위11.8％,무확증75례,점88.2％.재유HER2기인확증적10례병례중,7례HER2단백면역조직화학위3+,2례위2+,1례위-/1+；75례무기인확증적병례,HER2단백면역조직화학3+위0례、2+위18례(24.0％),-/1+위57례(76.0％).HER2기인확증여HER2단백표체적상부솔위77.6％.조직학상,유HER2양성확증적위암절대다수위중등분화관상선암.결론 쌍중원위잡교기술시검측위암활검조직HER2기인확증적가고화객관방법.림상상,부소수유HER2기인확증적위암괄합항HER2파향치료.
Objective To explore the status of HER2 gene amplification and its product HER2 protein expression in gastric carcinoma, so as to aid in patient selection for anti-HER2 targeted chemotherapy.Methods Eighty-five cases of gastric carcinoma biopsy tissues were collected.The status of HER2 gene amplification was detected by dual in situ hybridization (dual-ISH).And HER2 protein was detected by immunohistochemistry.Results HER2 gene amplification was detected in 10/85 ( 11.8％ )cases of gastric carcinoma,and no amplification was detected in 75/85 (88.2％ ) cases.In the 10 cases with HER2 amplification,HER2 immunoreaction scorings of 3 +,2 + and 0/1 + were present in 7,2 and 1 cases,respectively.In the 75 cases without HER2 amplification,HER2 immunoreaction scorings of 3 +,2 + and 0/1 + were present in 0,18 (24.0％ ) and 57 (76.0％ ) cases,respectively.Histologically,most gastric carcinoma with amplification of HER2 gene was moderately differentiated tubular adenocarcinoma.Conclusions HER2 gene dual-ISH technique is a reliable and objective method for detecting HER2 gene amplification in gastric carcinoma biopsy. Clinically, only few gastric carcinomas show HER2 gene amplification and are suitable candidates for anti-HER2 targeted chemotherapy.
